Proactive Investors - Run By Investors For Investors

Port Erin Biopharma Investments Ltd's interim expose NAV disparity

The investment company's shares rose 10% to 5.5p in early deals, barely half the net asset value per share
Port Erin Biopharma Investments Ltd's interim expose NAV disparity
The company's three main investments are Magna Biopharma, Plethora Solutions and Summit Therapeutics

Investment company Port Erin Biopharma Investments Ltd (LON:PEBI) said its three main investments continue to show significant growth potential.

Shares in the company rose 10% to 5.5p in early deals on the back of interim results that indicated the company's shares have a net asset value of 10.8p.

The company's three main investments are Magna Biopharma Income Fund (MBIF), Plethora Solutions Holdings PLC (LON:PLE) and Summit Therapeutics PLC (LON:SUMM).

MBIF's investment objective continues to seek growing income distributions with capital appreciation potential in the long term by investing in a diversified portfolio of biopharma sector securities. The company said prospects for the investment “remain compelling”.

Plethora has been taken over by Regent Pacific Group, giving Port Erin a stake in Hong Kong-listed Regent.

Summit is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy (DMD) and infections caused by the bacteria C. difficile (CDI).

Summit's progress has been extensively covered on Proactive Investors.

During the reporting period the company invested £94,995 in the Diabetic Boot Company, a company focused on treating diabetic foot ulcers.

Investment income in the six months to the end of 2015 was negative at £96,448 compared to £83,835 the year before.

Loss before tax widened to £184,674 from £143,388 in the same period of 2014, although given the company's focus on early-stage biopharmaceutical companies, the results are not particularly meaningful and investors tend to focus on the net asset value per share, which is currently substantially higher than the share price.

"Your board is currently considering a number of further options which show significant promise in being able to eliminate the substantial discount to net asset value in line with the investing policy adopted in November 2013," said Jim Mellon, non-executive chairman of Port Erin.


Register here to be notified of future PEBI Company articles

Related Articles

cancer cells
January 24 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use